Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.24 – $0.275
Volume110,710
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4M
Price / earnings
—
Price / book
2.36×
Price / sales
—
EV / sales
—
EV / EBITDA
0.05×
Profitability
Earnings per share
-$1.09
Return on assets
-145.91%
Return on equity
-989.71%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.93×
Quick ratio
0.93×
Cash ratio
0.52×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TRAW, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$2.73M
$57K
$56K
$57K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$2.73M
$57K
$56K
$57K
Selling, general and administrative
$3.48M
$2.03M
$2.33M
$1.74M
$1.69M
$2.75M
$3.48M
$3.48M
Research and development
$1.1M
$4.91M
$5.04M
$2.31M
$2.29M
$2.51M
$1.86M
$5.11M
Total operating expenses
$3.18M
$6.95M
$7.37M
$4.06M
$3.98M
$5.26M
$5.33M
$8.59M
Operating income
-$3.18M
-$6.95M
-$7.37M
-$4.06M
-$1.25M
-$5.2M
-$5.28M
-$8.54M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$3.05M
-$7.11M
-$7.44M
-$3.96M
-$915K
$21.49M
-$29.92M
-$8.48M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.05M
-$7.11M
-$7.44M
-$3.96M
-$915K
$21.49M
-$29.92M
-$8.48M
Net income attributable to common shareholders
-$2.61M
-$5.69M
-$5.4M
-$3.04M
-$625K
$15.08M
-$21.42M
-$1.43M
EBITDA
-$3.13M
-$6.9M
-$7.32M
-$4.04M
-$1.25M
-$5.2M
-$5.28M
-$8.53M
Basic earnings per share
-$0.16
-$0.53
-$0.48
-$0.34
-$0.11
$2.17
-$6.31
-$1.49
Diluted earnings per share
-$0.16
-$0.53
-$0.46
-$0.34
-$0.11
$2.09
-$6.31
-$1.49
Recent news
Company coverage with links to the original publishers.
Traws Pharma announced the deferral of its Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA. While the compound showed potent efficacy in animal models, the company is advancing backup candidates with similar pharmacokinetic profiles while maintaining cash runway through Q1 2027.
Traws Pharma initiated Phase 2 clinical trials for ratutrelvir, a ritonavir-free COVID-19 treatment, comparing its safety and efficacy against PAXLOVID®. The company expects to report trial results by year-end 2025, targeting potential improvements in COVID treatment.
Traws Pharma, a clinical-stage biopharmaceutical company, is developing novel antiviral therapies targeting respiratory viral diseases like bird flu, seasonal influenza, and COVID-19. The company submitted a Phase 2 protocol for tivoxavir marboxil and briefing documents to the FDA for a Type D meeting.
Traws Pharma announces the publication of positive clinical data for its legacy oncology drug rigosertib in treating recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma (RDEB SCC), a rare and aggressive form of skin cancer.